138 related articles for article (PubMed ID: 16209703)
1. Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy.
Faunce T; Doran E; Henry D; Drahos P; Searles A; Pekarsky B; Neville W
Global Health; 2005 Oct; 1():15. PubMed ID: 16209703
[TBL] [Abstract][Full Text] [Related]
2. Will the Australia-United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?
Harvey KJ; Faunce TA; Lokuge B; Drahos P
Med J Aust; 2004 Sep; 181(5):256-9. PubMed ID: 15347273
[TBL] [Abstract][Full Text] [Related]
3. Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal.
Faunce TA
Aust New Zealand Health Policy; 2007 Jun; 4():9. PubMed ID: 17543114
[TBL] [Abstract][Full Text] [Related]
4. The UNESCO Bioethics Declaration 'social responsibility' principle and cost-effectiveness price evaluations for essential medicines.
Faunce TA
Monash Bioeth Rev; 2005 Jul; 24(3):10-9. PubMed ID: 16302317
[TBL] [Abstract][Full Text] [Related]
5. Free trade in pharmaceuticals.
Outterson MK
Med J Aust; 2004 Sep; 181(5):260-1. PubMed ID: 15347274
[TBL] [Abstract][Full Text] [Related]
6. The PBS in a globalised world: free trade and reference pricing.
Searles A
Aust Health Rev; 2009 May; 33(2):186-91. PubMed ID: 19563307
[TBL] [Abstract][Full Text] [Related]
7. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
[TBL] [Abstract][Full Text] [Related]
8. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
Doran E; Alexander Henry D
J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
[TBL] [Abstract][Full Text] [Related]
9. Patents, pills and politics: the Australia-United States Free Trade Agreement and the Pharmaceutical Benefits Scheme.
Harvey K
Aust Health Rev; 2004 Nov; 28(2):218-26. PubMed ID: 15527402
[TBL] [Abstract][Full Text] [Related]
10. Intellectual property and access to medicines: mapping public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process.
Wong ASY; Cole CB; Kohler JC
Global Health; 2021 Aug; 17(1):92. PubMed ID: 34416883
[TBL] [Abstract][Full Text] [Related]
11. The high price of "free" trade: U.S. trade agreements and access to medicines.
Lopert R; Gleeson D
J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
[TBL] [Abstract][Full Text] [Related]
12. The Trans-Pacific Partnership Agreement: challenges for Australian health and medicine policies.
Faunce TA; Townsend R
Med J Aust; 2011 Jan; 194(2):83-6. PubMed ID: 21241222
[TBL] [Abstract][Full Text] [Related]
13. What Generates Attention to Health in Trade Policy-Making? Lessons From Success in Tobacco Control and Access to Medicines: A Qualitative Study of Australia and the (Comprehensive and Progressive) Trans-Pacific Partnership.
Townsend B; Friel S; Schram A; Baum F; Labonté R
Int J Health Policy Manag; 2021 Oct; 10(10):613-624. PubMed ID: 32610761
[TBL] [Abstract][Full Text] [Related]
14. The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia.
Faunce TS; Tomossy GF
Monash Bioeth Rev; 2005 Apr; 24(2):38-42. PubMed ID: 16208881
[TBL] [Abstract][Full Text] [Related]
15. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
Adekola TA
Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
[TBL] [Abstract][Full Text] [Related]
16. What is the impact of intellectual property rules on access to medicines? A systematic review.
Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
[TBL] [Abstract][Full Text] [Related]
17. Policy challenges of nanomedicine for Australia's PBS.
Faunce TA
Aust Health Rev; 2009 May; 33(2):258-67. PubMed ID: 19563314
[TBL] [Abstract][Full Text] [Related]
18. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
19. Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis.
Son KB
Global Health; 2020 Oct; 16(1):98. PubMed ID: 33054820
[TBL] [Abstract][Full Text] [Related]
20. Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: enhancing an endangered global public good.
Faunce TA
Global Health; 2006 Mar; 2():5. PubMed ID: 16569240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
